ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2062

Increasing Pneumococcal Vaccination for Immunosuppressed Patients: A Cluster Quality Improvement Trial

Sonali Desai1, Lara Szent-gyorgyi2, Alexander Turchin3, Bing Lu4, Anna A. Bogdanova2, Michael Weinblatt5, Jonathan S. Coblyn6, Jeffrey O. Greenberg2, Allen Kachalia2 and Daniel H. Solomon7, 1Medicine/ Rheumatology, Boston, MA, 2Medicine, Boston, MA, 3Endocrinology, Boston, MA, 4Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 5Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, 6Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 7Division of Rheumatology, Brigham and Women's Hospital, Boston, MA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Quality of care and vaccines

  • Tweet
  • Email
  • Print
Session Information

Title: Quality Measures and Innovations in Practice Management and Care Delivery

Session Type: Abstract Submissions (ACR)

Increasing Pneumococcal Vaccination for Immunosuppressed Patients:

A Cluster Quality Improvement Trial

Background/Purpose:   It is important for patients on immunosuppressive medications to receive pneumococcal vaccination. Prior studies suggest that most patients do not undergo vaccination. We evaluated the effects of a point-of-care paper reminder form on being up-to-date with pneumococcal vaccination in a rheumatology practice.

Methods: Selected rheumatologists at five ambulatory practice sites received a point-of-care paper reminder form for patients who were not up-to-date with pneumococcal vaccination. Interrupted time-series analyses were used to measure the effect of the paper reminder form upon the intervention rheumatologists compared to the control rheumatologists.  Adjusted Cox proportional hazards models were examined to identify independent predictors of being up-to-date with pneumococcal vaccination.

Results: We evaluated a total of 3,717 patients on immunosuppressive medications. In this group 66.0% had rheumatoid arthritis:74.1% were female, and the mean age was 53.7 years. Rheumatologists who received the intervention had a significant increase in the rate of patients up-to-date with pneumococcal vaccination from 67.6% to 80.0% in the time period following the intervention (p=0.006), whereas rheumatologists in the control group had stable rate from 52.3% to 52.0% (p=0.90). In regression models, the intervention [hazard ratio, HR=3.58, (95% CI 2.46-5.20)], having a primary care physician affiliated with our hospital [HR=1.68, (95% CI 1.44-1.97)], and having a diagnosis of diabetes mellitus [HR =1.57, (95% CI 1.02-2.41)] were positive predictors of being up-to-date with vaccination.

Conclusion:  A simple point-of-care paper reminder for patients on immunosuppressive medications significantly increased the rate of being up-to-date with pneumococcal vaccination among intervention rheumatologists over a six-month period.

Figure 1. Pneumococcal vaccination over time, before and after point-of-care reminder intervention 

Figure 1 shows the percentage of patients up-to-date with pneumococcal vaccination over time. The intervention was applied in two waves, with ten physicians receiving the intervention in June 2010 and four additional physicians receiving the intervention in October 2010. In order to synchronize these data, time 0 was defined as the time that the intervention was applied to the patients of the treating rheumatologist. The red line represents the 21 rheumatologists in the control group and the blue line represents the 14 rheumatologists in the intervention group.


Disclosure:

S. Desai,
None;

L. Szent-gyorgyi,
None;

A. Turchin,
None;

B. Lu,
None;

A. A. Bogdanova,
None;

M. Weinblatt,

MedImmune,

2,

Crescendo Bioscience,

2,

MedImmune,

5,

Crescendo Bioscience,

5;

J. S. Coblyn,

CVS,

5;

J. O. Greenberg,
None;

A. Kachalia,
None;

D. H. Solomon,

Abbott Immunology Pharmaceuticals,

2,

Lilly,

2,

Corrona,

5,

Up To Date,

7.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increasing-pneumococcal-vaccination-for-immunosuppressed-patients-a-cluster-quality-improvement-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology